EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Association of Altered Plasma Lipidome with Disease Severity in COVID-19 Patients

Zhengzheng Zhang, Naama Karu iD, Alida Kindt iD, Madhulika Singh iD, Lieke Lamont iD, Adriaan J van Gammeren, Anton A M Ermens, Amy C Harms iD, Lutzen Portengen, Roel C H Vermeulen, Willem A Dik iD, Anton W Langerak iD und 2 weitere

Biomolecules · 2024

DOI: 10.3390/biom14030296 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomolecules, 2024. Verfasst von Zhengzheng Zhang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Metabolomics and Analytics Centre, Leiden Academic Centre for Drug Research, Leiden University, 2333 CC Leiden, The Netherlands. Hauptthemen laut MEDLINE: Sphingosine, COVID-19. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NWO, MXL Fieldlab, MetaCovid.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The severity of COVID-19 is linked to an imbalanced immune response. The dysregulated metabolism of small molecules and bioactive lipids has also been associated with disease severity. To promote understanding of the disease biochemistry and provide targets for intervention, we applied a range of LC-MS platforms to analyze over 100 plasma samples from patients with varying COVID-19 severity and with detailed clinical information on inflammatory responses (>30 immune markers). This is the third publication in a series, and it reports the results of comprehensive lipidome profiling using targeted LC-MS/MS. We identified 1076 lipid features across 25 subclasses, including glycerophospholipids, sterols, glycerolipids, and sphingolipids, among which 531 lipid features were dramatically changed in the plasma of intensive care unit (ICU) patients compared to patients in the ward. Patients in the ICU showed 1.3–57-fold increases in ceramides, (lyso-)glycerophospholipids, diglycerides, triglycerides, and plasmagen phosphoethanolamines, and 1.3–2-fold lower levels of a cyclic lysophosphatidic acid, sphingosine-1-phosphates, sphingomyelins, arachidonic acid-containing phospholipids, lactosylceramide, and cholesterol esters compared to patients in the ward. Specifically, phosphatidylinositols (PIs) showed strong fatty acid saturation-dependent behavior, with saturated fatty acid (SFA)- and monosaturated fatty acid (MUFA)-derived PI decreasing and polystaturated (PUFA)-derived PI increasing. We also found ~4000 significant Spearman correlations between lipids and multiple clinical markers of immune response with |R| ≥ 0.35 and FDR corrected Q < 0.05. Except for lysophosphatidic acid, lysophospholipids were positively associated with the CD4 fraction of T cells, and the cytokines IL-8 and IL-18. In contrast, sphingosine-1-phosphates were negatively correlated with innate immune markers such as CRP and IL-6. Further indications of metabolic changes in moderate COVID-19 disease were demonstrated in recovering ward patients compared to those at the start of hospitalization, where 99 lipid species were altered (6 increased by 30–62%; 93 decreased by 1.3–2.8-fold). Overall, these findings support and expand on early reports that dysregulated lipid metabolism is involved in COVID-19.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SphingosineCOVID-19HumansLipidomicsChromatography, LiquidTandem Mass SpectrometryFatty AcidsGlycerophospholipidsLysophospholipidsBiomarkersPatient AcuityPhosphates

Stichwörter der Autor:innen

COVID-19SARS-CoV-2cytokineinflammationlipidomicslipids

Substanzen

sphingosine 1-phosphateSphingosineFatty AcidsGlycerophospholipidsLysophospholipidsBiomarkersPhosphates

Autor:innen und Institutionen

  • Metabolomics and Analytics Centre, Leiden Academic Centre for Drug Research, Leiden University, 2333 CC Leiden, The Netherlands.
  • Tasmanian Independent Metabolomics and Analytical Chemistry Solutions (TIMACS), Hobart, TAS 7008, Australia.
  • Department of Clinical Chemistry and Hematology, Amphia Hospital, 4818 CK Breda, The Netherlands.
  • Department of Population Health Sciences, Institute for Risk Assessment Sciences, University Utrecht, 3584 CK Utrecht, The Netherlands.
  • Laboratory Medical Immunology, Department of Immunology, Erasmus MC University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands.

ORCID-Profile: Naama Karu, Alida Kindt, Madhulika Singh, Lieke Lamont, Amy C Harms, Willem A Dik, Anton W Langerak, Vincent H J van der Velden, Thomas Hankemeier

Förderung

  • NWO
  • MXL Fieldlab
  • MetaCovid
  • TKI-LSH project ‘METACOVID’
  • NWA project ‘Measuring and detection of health’
  • European Funds for Regional Development (Kansen voor West II: Phenomix Fieldlab)

Zitieren

APA

Zhang, Z., Karu, N., Kindt, A., Singh, M., Lamont, L., van Gammeren, A. J., Ermens, A. A. M., Harms, A. C., Portengen, L., Vermeulen, R. C. H., Dik, W. A., Langerak, A. W., van der Velden, V. H. J., & Hankemeier, T. (2024). Association of Altered Plasma Lipidome with Disease Severity in COVID-19 Patients. Biomolecules. https://doi.org/10.3390/biom14030296

Vancouver

Zhang Z, Karu N, Kindt A, Singh M, Lamont L, van Gammeren AJ, et al. Association of Altered Plasma Lipidome with Disease Severity in COVID-19 Patients. Biomolecules. 2024. doi:10.3390/biom14030296

BibTeX
@article{Zhang2024,
  author = {Zhang, Zhengzheng and Karu, Naama and Kindt, Alida and Singh, Madhulika and Lamont, Lieke and van Gammeren, Adriaan J and Ermens, Anton A M and Harms, Amy C and Portengen, Lutzen and Vermeulen, Roel C H and Dik, Willem A and Langerak, Anton W and van der Velden, Vincent H J and Hankemeier, Thomas},
  title = {Association of Altered Plasma Lipidome with Disease Severity in COVID-19 Patients},
  journal = {Biomolecules},
  year = {2024},
  doi = {10.3390/biom14030296}
}
Kostenlos starten →